About Free fatty acid receptor 3
Free fatty acid receptor 3 (FFAR3) is a protein
from Homo sapiens identified by UniProt accession
O14843, 346 residues long.
MolForge cross-references it against 0 known binders and
113 disease associations.
Target properties
| Protein name | Free fatty acid receptor 3 |
| UniProt accession | O14843 |
| Gene | FFAR3 |
| Organism | Homo sapiens |
| Length | 346 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (113)
Diseases linked to this target (Open Targets).
- glioblastoma multiforme · score 0.25
- breast adenocarcinoma · score 0.24
- low grade glioma · score 0.12
- MODY · score 0.08
- hyperinsulinism due to INSR deficiency · score 0.07
- hyperinsulinism due to glucokinase deficiency · score 0.06
- hyperproinsulinemia · score 0.06
- exercise-induced hyperinsulinism · score 0.05
- diabetes mellitus, transient neonatal, 2 · score 0.05
- hyperinsulinemic hypoglycemia, familial, 4 · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O14843-F1 | alphafold | PREDICTED | 86.36 | — |
Amino-acid sequence (346 residues)
MDTGPDQSYF SGNHWFVFSV YLLTFLVGLP LNLLALVVFV GKLQRRPVAV DVLLLNLTAS DLLLLLFLPF RMVEAANGMH WPLPFILCPL SGFIFFTTIY LTALFLAAVS IERFLSVAHP LWYKTRPRLG QAGLVSVACW LLASAHCSVV YVIEFSGDIS HSQGTNGTCY LEFRKDQLAI LLPVRLEMAV VLFVVPLIIT SYCYSRLVWI LGRGGSHRRQ RRVAGLLAAT LLNFLVCFGP YNVSHVVGYI CGESPAWRIY VTLLSTLNSC VDPFVYYFSS SGFQADFHEL LRRLCGLWGQ WQQESSMELK EQKGGEEQRA DRPAERKTSE HSQGCGTGGQ VACAES
Explore Free fatty acid receptor 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets